Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
5(38%)
Results Posted
0%(0 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_1
6
46%
Ph phase_2
4
31%
Ph phase_3
2
15%
Ph not_applicable
1
8%

Phase Distribution

6

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
6(46.2%)
Phase 2Efficacy & side effects
4(30.8%)
Phase 3Large-scale testing
2(15.4%)
N/ANon-phased studies
1(7.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

5

trials recruiting

Total Trials

13

all time

Status Distribution
Active(5)
Completed(3)
Terminated(2)
Other(3)

Detailed Status

Recruiting4
unknown3
Completed3
Withdrawn1
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
5
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (46.2%)
Phase 24 (30.8%)
Phase 32 (15.4%)
N/A1 (7.7%)

Trials by Status

recruiting431%
withdrawn18%
unknown323%
terminated18%
completed323%
active_not_recruiting18%

Recent Activity

5 active trials
Showing 5 of 13
recruitingphase_3

A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

NCT06389292
recruitingphase_3

Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

NCT06641414
active_not_recruitingphase_1

Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

NCT03843528
terminatedphase_1

Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]

NCT06150040
recruitingphase_2

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

NCT06316960
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT06389292Phase 3

A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

Recruiting
NCT06641414Phase 3

Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

Recruiting
NCT03843528Phase 1

Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

Active Not Recruiting
NCT06150040Phase 1

Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]

Terminated
NCT06316960Phase 2

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Recruiting
NCT06078306Phase 2

CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).

Unknown
NCT06279338Not Applicable

A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score

Unknown
NCT05048498Phase 1

Pharmacokinetics, Tolerability and Safety of NEX-18a

Completed
NCT03941496Phase 1

Azacytidine During Anti-tuberculosis Therapy

Withdrawn
NCT05048615Phase 2

Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML

Completed
NCT05559008Phase 1

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Unknown
NCT04913922Phase 2

Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML

Recruiting
NCT00005639Phase 1

Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13